Trial Profile

The Safety, Tolerability, Pharmacokinetic Characteristics and Efficacy of KM257 in Patients With Advanced HER2-positive or Expressing Solid Tumors in a Single-arm, Open-label, Multi-center Phase 1 Clinical Study.

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 18 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs KM 257 (Primary) ; Capecitabine; Carboplatin; Cisplatin; Docetaxel; Gemcitabine; Irinotecan; Paclitaxel
Indications Solid tumours
Focus Adverse reactions; First in man; Therapeutic Use
Sponsors Xuanzhu Biopharmaceutical

08 Apr 2022 Status changed from planning to not yet recruiting.
28 Mar 2022 New trial record
08 Mar 2022 According to a Xuanzhu Biopharmaceutical media release, XZP-KM257 has been approved by the National Medical Products Administration ("NMPA") of the People's Republic of China ("China") to initiate this trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com